Disease · MONDO_0005011

Crohn disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Crohn disease. Diseases, record MONDO_0005011. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005011

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Crohn disease; Open Targets
Open Targets ID: MONDO_0005011; Open Targets
Other names: CROHN DIS, CROHNS DIS, Colitis, Granulomatous, Crohn's associated gastritis, Crohn's disease, Crohn's disease of large bowel, Crohns Disease, Enteritis, Granulomatous, Enteritis, Regional, Gastritis Associated with Crohn Disease, Gastritis Associated with Crohn's Disease, Ileitis, Regional, Ileitis, Terminal, Ileocolitis, paediatric Crohn's disease, pediatric Crohn's disease, regional enteritis; Open Targets
Disease Ontology: DOID:8778; Disease Ontology
MeSH: D003424; MeSH
NCI Thesaurus: C2965; NCI Thesaurus
Orphanet: ORPHA:206; Orphanet
Highest stage of its drugs: Approval, for 23 of its 198 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs198

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
INFLIXIMAB	CHEMBL1201581	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	109	97	96	Drugs and targets
ADALIMUMAB	CHEMBL1201580	Antibody	Approval	EMA Human Drugs and PMDA	85	67	66	Drugs and targets
USTEKINUMAB	CHEMBL1201835	Antibody	Approval	DailyMed, EMA Human Drugs and PMDA	73	55	55	Drugs and targets
VEDOLIZUMAB	CHEMBL1743087	Antibody	Approval	DailyMed, EMA Human Drugs and TTD	56	52	52	Drugs and targets
CERTOLIZUMAB PEGOL	CHEMBL1201831	Antibody	Approval	DailyMed	31	29	29	Drugs and targets
AZATHIOPRINE	CHEMBL1542	Small molecule	Approval	PMDA	22	21	21	Drugs and targets
RISANKIZUMAB	CHEMBL3990029	Antibody	Approval	EMA Human Drugs and PMDA	21	18	18	Drugs and targets
GUSELKUMAB	CHEMBL2364648	Antibody	Approval	EMA Human Drugs	19	18	18	Drugs and targets
UPADACITINIB	CHEMBL3622821	Small molecule	Approval	EMA Human Drugs	18	16	16	Drugs and targets
MIRIKIZUMAB	CHEMBL3990014	Antibody	Approval	PMDA	14	13	13	Drugs and targets

1 to 10 of 198

See all 198 drugs

Targets140

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
NR3C1	Glucocorticoid receptor	11	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
IL12B	Interleukin-12	6	Interleukin-12 inhibitor; Interleukin-23 inhibitor	Approval	https://conductscience.org/library/genes/3593	Drugs and targets
IL23A	Interleukin-23	6	Interleukin-23 inhibitor	Approval	https://conductscience.org/library/genes/51561	Drugs and targets
TNF	Tumor necrosis factor	6	TNF-alpha inhibitor	Approval	https://conductscience.org/library/genes/7124	Drugs and targets
TYK2	Janus Kinase (JAK)	6	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator	Approval	https://conductscience.org/library/genes/7297	Drugs and targets
JAK1	Janus Kinase (JAK)	5	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Approval	https://conductscience.org/library/genes/3716	Drugs and targets
JAK3	Janus Kinase (JAK)	5	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Approval	https://conductscience.org/library/genes/3718	Drugs and targets
ITGB7	Integrin alpha-4/beta-7	4	Integrin alpha-4/beta-7 inhibitor; Integrin beta-7 antagonist	Approval	https://conductscience.org/library/genes/3695	Drugs and targets
JAK2	Janus Kinase (JAK)	4	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Approval	https://conductscience.org/library/genes/3717	Drugs and targets
CSF3R	Granulocyte colony-stimulating factor receptor	3	Granulocyte colony stimulating factor receptor agonist	Phase 1/2	https://conductscience.org/library/genes/1441	Drugs and targets

1 to 10 of 140

See all 140 targets

Trials569

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 12 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00844285	SECURE, the Cimzia ® Crohn's Disease Post-Marketing Registry		3,072	2023-05-06	Crohn's Disease	CERTOLIZUMAB PEGOL	Its record names the disease	ClinicalTrials.gov
NCT00705614	Postmarketing Safety Surveillance European Registry of Crohn's Disease Patients Treated With Remicade or Standard Therapy (MK-2155-035)		2,662	2014-08-26	Crohn's Disease	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02539368	Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease		2,565	2020-02-13	Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn's Disease	INFLIXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00790933	An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease	Phase 3	2,243	2019-03-12	Ulcerative Colitis, Crohn's Disease	VEDOLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT03466411	A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease	Phase 2/3	1,409	2025-05-07	Crohn's Disease	GUSELKUMAB	Its record names the disease	ClinicalTrials.gov
NCT02914561	Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease	Phase 3	1,372	2023-12-18	Crohn's Disease	FILGOTINIB	Its record names the disease	ClinicalTrials.gov
NCT01369355	A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)	Phase 3	1,282	2017-02-23	Crohn's Disease, Colitis, IBD, Inflammatory Bowel Disease	USTEKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT02914600	Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease	Phase 3	1,188	2024-07-10	Crohn's Disease	FILGOTINIB	Its record names the disease	ClinicalTrials.gov
NCT03926130	A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease	Phase 3	1,158	2024-12-27	Crohn's Disease	MIRIKIZUMAB, USTEKINUMAB	Its record names the disease	ClinicalTrials.gov
NCT00783692	Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease	Phase 3	1,116	2014-07-21	Crohn's Disease	VEDOLIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 569

See all 569 trials

Comparisons in its trials213

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Vedolizumab 300 mg (UC) vs Vedolizumab 300 mg (CD): Number of Participants With at Least One Clinically Significant Electrocardiogram (ECG) Findings	7 of 894	7 of 1,349	2,243	NCT00790933	Trial comparisons
Part 1 (OLE): Etrolizumab vs Part 2 (PML SM): deaths from any cause	3 of 751	1 of 359	1,110	NCT02403323	Trial comparisons
Part 1 (OLE): Etrolizumab vs Part 2 (PML SM): serious adverse events	206 of 751	1 of 359	1,110	NCT02403323	Trial comparisons
Treatment 1 vs Treatment 2: deaths from any cause	0 of 416	0 of 207	623	NCT03440372	Trial comparisons
Treatment 1 vs Treatment 2: serious adverse events	27 of 416	10 of 207	623	NCT03440372	Trial comparisons
Ozanimod vs Placebo: deaths from any cause	0 of 404	0 of 202	606	NCT03440385	Trial comparisons
Ozanimod vs Placebo: serious adverse events	24 of 404	11 of 202	606	NCT03440385	Trial comparisons
Maintenance Period: Treat to Target vs Maintenance Period: Routine Care: Number of Participants With Adverse Events (AEs) That Occurred in Participants Administered With Ustekinumab up to Week 48	188 of 219	179 of 221	440	NCT03107793	Trial comparisons
Certolizumab Pegol vs Placebo: serious adverse events	12 of 223	8 of 215	438	NCT00552058	Trial comparisons
Vedolizumab vs Placebo: serious adverse events	13 of 209	16 of 207	416	NCT01224171	Trial comparisons

1 to 10 of 213

See all 213 comparisons in its trials

Papers from its trials339

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
40113101	RESULT	2	PubMed
37224198	RESULT	4	PubMed
35842121	RESULT	2	PubMed
35673354	RESULT	1	PubMed
35644166	RESULT	1	PubMed
33922391	RESULT	1	PubMed
33676969	RESULT	2	PubMed
33599356	RESULT	1	PubMed
31633731	RESULT	1	PubMed
30114224	RESULT	1	PubMed

1 to 10 of 339

See all 339 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005011

GET https://conductscience.org/api/diseases/v1/MONDO_0005011/drugs?page=2

API reference For AI assistants